Advertisement

Reactions Weekly

, Volume 1780, Issue 1, pp 80–80 | Cite as

Brigatinib/crizotinib

Development of resistance to brigatinib and crizotinibin in non-small cell lung cancer: case report
Case report
  • 56 Downloads

Reference

  1. Sharma GG, et al. A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib. Journal of Thoracic Oncology 14: e257-e259, No. 11, Nov 2019. Available from: URL: http://doi.org/10.1016/j.jtho.2019.06.028 - ItalyCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations